Lactobacillus acidophilus and bifidobacterium bifidum reduce chronic HCV progression: Thesis Abstract

Thesis Abstract Background: Hepatitis C virus (HCV) is a major leading cause of pathogenesis liver disease which was treated with IFN-based therapy and recently Sovaldi®. There challenge to explore new drugs. Probiotics are the most common natural therapeutic that can ameliorate dysfunction. Aim: study antiviral antibacterial responses probiotics in patients chronic (HCV). Materials Methods: were IFN/ribavirin, or both IFN capsule containing L. acidophilus Bifidobacterium spp. administered as one per day for month. Blood urine samples collected before after treatment strategies processed quantitative determination HCV PCR assay, identification bacteria by VITEK2 system 16S r RNA gene sequencing, estimation activity, well counts leukocytes CD3+ T cells CD56+ killer cells. Results: Treatment Bifidobacteria enhanced IFN-α ribavirin treatment, shown viral titter assay clarified activity also against bacterial infections HCV. Additionally, it increased numbers CD56+, Conclusions: act supportive supplement antiviral, positive immune response activities